FDMT CEO sells 69K shares after option exercise

4D Molecular Therapeutics, Inc. (FDMT) reported that President and Chief Executive Officer David Kirn exercised stock options for 50,000 shares of common stock at an exercise price of $4.14 per share, reducing that option position to 217,500 options remaining.

Rhea-AI Filing Summary

4D Molecular Therapeutics, Inc. (FDMT) reported that President and Chief Executive Officer David Kirn exercised stock options for 50,000 shares of common stock at an exercise price of $4.14 per share, reducing that option position to 217,500 options remaining. He then sold a total of 69,076 common shares in open-market transactions on August 19, 2026, including 43,149 shares at a weighted average price of $15.3566 (within a range of $14.91–$15.84) and 25,927 shares at a weighted average price of $16.4173 (within a range of $15.97–$16.65). The filing states these trades were made pursuant to a Rule 10b5-1 trading plan adopted on January 9, 2026.

Insider Trade Summary 10b5-1

Exercise and sale activity reported; no spread calculated

Exercise and Sale 4 txns

Insider Kirn David

Role See Remarks

Sold 69,076 shs ($1.09M)

Approx. gross sale proceeds $1.09M

Approx. exercise cost $207K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy) F1, F4	50,000	$0.00	$0.00
Exercise	Common Stock F1	50,000	$4.14	$207K
Sale	Common Stock F1, F2	43,149	$15.3566	$663K
Sale	Common Stock F1, F3	25,927	$16.4173	$426K

Holdings After Transaction: Stock Option (Right to Buy) — 217,500 contracts (Direct); Common Stock — 825,819 shares (Direct)

Footnotes (4)

1. F1. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026.
2. F2. The transaction was executed in multiple trades in prices ranging from $14.91 to $15.84, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
3. F3. The transaction was executed in multiple trades in prices ranging from $15.97 to $16.65, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
4. F4. The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.

Key Figures

Options exercised: 50,000 shares Exercise price: $4.14 per share Options remaining after exercise: 217,500 options +4 more

7 metrics

Options exercised 50,000 shares Stock option exercise on August 19, 2026 at $4.14 per share

Exercise price $4.14 per share Exercise price for 50,000 stock options into FDMT common stock

Options remaining after exercise 217,500 options Stock option position following the 50,000-share exercise

First sale tranche 43,149 shares at $15.3566 Weighted average sale price within $14.91–$15.84 range on August 19, 2026

Second sale tranche 25,927 shares at $16.4173 Weighted average sale price within $15.97–$16.65 range on August 19, 2026

Total shares sold 69,076 shares Aggregate FDMT common shares sold in two sale transactions

Option vesting schedule 1/48th monthly over 4 years Option vests monthly from March 6, 2025, fully vested on fourth anniversary

Key Terms

Rule 10b5-1 trading plan, weighted average sale price, Vesting Commencement Date, stock option award

4 terms

Rule 10b5-1 trading plan regulatory

"Transaction made pursuant to a 10b5-1 trading plan adopted"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sale price financial

"The price reported in Column 4 above reflects the weighted average sale price"

Vesting Commencement Date financial

"on each monthly anniversary of March 6, 2025 (the "Vesting Commencement Date")"

The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.

stock option award financial

"The shares underlying the stock option award shall vest and become exercisable"

A stock option award is a grant that gives an employee the right to buy a company’s shares at a fixed price for a limited time, often becoming available gradually over a set schedule. Investors care because these awards align workers’ incentives with company performance, can increase employee loyalty, and may create future share dilution and compensation expense that affect earnings per share and shareholder value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did FDMT CEO David Kirn report in this Form 4 transaction?

He exercised options for 50,000 FDMT shares at $4.14 per share and then sold 69,076 common shares in open-market transactions on August 19, 2026, under a Rule 10b5-1 trading plan.

How many FDMT shares did David Kirn sell and at what prices?

He sold 69,076 FDMT common shares on August 19, 2026: 43,149 shares at a weighted average of $15.3566 (range $14.91–$15.84) and 25,927 shares at a weighted average of $16.4173 (range $15.97–$16.65).

What stock options did David Kirn exercise in FDMT?

He exercised 50,000 stock options for FDMT common stock at an exercise price of $4.14 per share. After this exercise, 217,500 options from that award remained outstanding, expiring on March 5, 2035.

Were the reported FDMT share sales by David Kirn under a Rule 10b5-1 plan?

Yes. The filing states the transactions were made pursuant to a Rule 10b5-1 trading plan adopted by David Kirn on January 9, 2026, which pre-arranged the trading activity disclosed.

How do David Kirn’s FDMT options vest according to this disclosure?

The filing states the stock option award vests as to 1/48th of the underlying shares each month starting from March 6, 2025, so the option becomes fully vested on the fourth anniversary while he remains a service provider.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/21/2026 - 04:06 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kirn David

(Last) (First) (Middle)

C/O 4D MOLECULAR THERAPEUTICS INC.

5858 HORTON STREET #455

(Street)

EMERYVILLE CALIFORNIA 94608

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
4D Molecular Therapeutics, Inc. [ FDMT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/19/2026		M(1)		50,000	A	$4.14	894,895	D
Common Stock	08/19/2026		S(1)		43,149	D	$15.3566(2)	851,746	D
Common Stock	08/19/2026		S(1)		25,927	D	$16.4173(3)	825,819	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$4.14	08/19/2026		M(1)			50,000	(4)	03/05/2035	Common Stock	50,000	$0	217,500	D

Explanation of Responses:

1. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026.

2. The transaction was executed in multiple trades in prices ranging from $14.91 to $15.84, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

3. The transaction was executed in multiple trades in prices ranging from $15.97 to $16.65, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

4. The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.

Remarks:

President and Chief Executive Officer

	/s/ Scott Bizily as Attorney-in-Fact for David Kirn	08/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)